Bulk Pharmaceutical API Sources for CHLOROPROCAINE HYDROCHLORIDE

Bulk Pharmaceutical API Sources for CHLOROPROCAINE HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-006-115-755
AvaChem Scientific		3858-89-7
AvaChem Scientific		2816
TargetMol		T6443
AKos Consulting & Solutions		AKOS027382305
ChemShuttle		141781

Bulk Chloroprocaine Hydrochloride API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the global supply of bulk chloroprocaine hydrochloride (CAS: 3858-54-0) active pharmaceutical ingredient (API). Key factors examined include major manufacturing regions, dominant suppliers, price trends, regulatory considerations, and patent activity impacting market access. The analysis focuses on identifying reliable and cost-effective sources for this local anesthetic, crucial for medical applications.

What are the Primary Manufacturing Regions for Chloroprocaine Hydrochloride API?

The production of chloroprocaine hydrochloride API is concentrated in several key geographical areas, driven by established pharmaceutical manufacturing infrastructure, access to raw materials, and regulatory compliance.

• China: This region is a significant global supplier, benefiting from large-scale chemical synthesis capabilities and a cost-competitive manufacturing environment. Numerous Chinese manufacturers produce chloroprocaine hydrochloride API, serving both domestic and international markets. The presence of a robust fine chemical industry underpins China's capacity.
• India: India is another major hub for API production, including chloroprocaine hydrochloride. Indian manufacturers are known for their adherence to international quality standards, such as Good Manufacturing Practices (GMP), and often possess advanced synthesis expertise. The country's strong pharmaceutical export sector contributes to its prominence.
• Europe: Certain European countries, particularly those with established chemical and pharmaceutical industries like Germany and Switzerland, also contribute to the global supply. European production often emphasizes high purity and strict regulatory adherence, catering to markets with stringent quality requirements.
• North America: While production volumes may be lower compared to Asia, North American manufacturers also produce chloroprocaine hydrochloride API. These facilities often focus on specialized production runs or cater to regional demand with a focus on immediate supply chain reliability.

The competitive landscape is characterized by a mix of large-scale commodity producers and smaller, more specialized manufacturers. Pricing is heavily influenced by production scale, raw material costs, and the stringency of regulatory certifications held by the producer.

Who are the Key Suppliers of Chloroprocaine Hydrochloride API?

Several companies globally are recognized for their consistent supply of chloroprocaine hydrochloride API. Supplier selection hinges on factors such as production capacity, quality certifications, regulatory filings (e.g., Drug Master Files - DMFs), and reliability of delivery.

Major Manufacturers and Suppliers:

• Xiamen Origin Chemical Co., Ltd. (China): A prominent supplier with a broad catalog of pharmaceutical intermediates and APIs, including chloroprocaine hydrochloride. They often cater to international markets and emphasize quality control.
• Changzhou Finer Chemical Co., Ltd. (China): Another significant Chinese producer of pharmaceutical chemicals. They are known for their synthesis capabilities and supply chain integration.
• Gennex Laboratories Ltd. (India): An established Indian API manufacturer with a diverse product portfolio. Gennex adheres to international GMP standards and supplies APIs for various therapeutic areas.
• Divi's Laboratories Limited (India): A large-scale Indian API manufacturer with extensive experience in complex chemical synthesis. While they may not exclusively list chloroprocaine hydrochloride, their broad API capabilities suggest potential supply.
• Hubei Biocause Pharmaceutical Co., Ltd. (China): A Chinese company with a focus on producing APIs and pharmaceutical intermediates, often serving global pharmaceutical companies.
• Alkem Laboratories Ltd. (India): A major Indian pharmaceutical company that also engages in API manufacturing. Their robust quality systems support global regulatory compliance.
• Aarti Drugs Ltd. (India): A well-established Indian API manufacturer with a wide range of products, including various anesthetic agents and intermediates.

The availability and pricing from these suppliers can fluctuate based on global demand, raw material availability, and geopolitical factors. Prospective buyers should conduct thorough due diligence, including site audits and quality agreement negotiations, before committing to significant supply contracts.

What are the Current Price Trends and Cost Drivers for Chloroprocaine Hydrochloride API?

The price of bulk chloroprocaine hydrochloride API is subject to several market dynamics. Historically, prices have been relatively stable, but recent global supply chain disruptions and raw material cost volatility have introduced fluctuations.

Key Price Determinants:

• Raw Material Costs: The synthesis of chloroprocaine hydrochloride relies on specific precursor chemicals. Fluctuations in the prices of these raw materials, driven by their own supply and demand dynamics, directly impact API production costs.
• Manufacturing Scale and Efficiency: Larger production batches generally lead to lower per-unit costs due to economies of scale. Manufacturers with highly efficient synthesis processes and lower overhead can offer more competitive pricing.
• Regulatory Compliance and Certification: APIs produced under stringent GMP conditions and supported by comprehensive regulatory documentation (e.g., CEP, DMF) often command higher prices. The cost of maintaining these standards is passed on to the buyer.
• Geopolitical Factors and Supply Chain Reliability: Disruptions in major manufacturing regions due to trade policies, environmental regulations, or public health crises can lead to price increases and supply shortages.
• Quality and Purity Specifications: Higher purity requirements or specific polymorphic forms can increase production complexity and cost.
• Demand: Seasonal or sudden surges in demand for chloroprocaine hydrochloride, driven by increased medical procedures or specific public health needs, can temporarily elevate prices.

Approximate Price Range (as of late 2023/early 2024):

Based on market intelligence and trade data, the bulk price for chloroprocaine hydrochloride API can range from $40 to $90 USD per kilogram. This range is highly variable and depends on the factors listed above, order volume, and the specific supplier's pricing structure. Smaller orders or those requiring expedited delivery will typically fall at the higher end of this spectrum.

It is crucial for purchasers to obtain multiple quotes and engage in direct negotiations with shortlisted suppliers. Long-term supply agreements can often secure more favorable pricing and predictable supply.

What Regulatory Considerations are Critical for Chloroprocaine Hydrochloride API Sourcing?

Sourcing chloroprocaine hydrochloride API requires strict adherence to pharmaceutical regulatory frameworks to ensure product safety, efficacy, and compliance with local and international health authorities.

Key Regulatory Requirements:

• Good Manufacturing Practices (GMP): Manufacturers must demonstrate compliance with relevant GMP guidelines, such as those established by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or World Health Organization (WHO). This ensures consistent quality control throughout the manufacturing process.
• Drug Master Files (DMFs) / Certificates of Suitability (CEPs): For APIs intended for use in regulated markets (e.g., U.S., Europe), suppliers should have a filed DMF (in the U.S.) or a CEP (in Europe). These documents provide regulatory authorities with confidential detailed information about the manufacturing process, controls, and facilities of the API. Pharmaceutical companies can reference these filings in their drug product applications.
• Impurity Profiling and Control: Manufacturers must have robust analytical methods to identify, quantify, and control impurities in the API. Limits for known and unknown impurities must meet pharmacopoeial standards (e.g., USP, EP) or be justified based on toxicological data.
• Stability Data: Suppliers must provide comprehensive stability data demonstrating the API's shelf-life under specified storage conditions. This data is essential for determining the expiry date of the finished drug product.
• Country-Specific Registrations: Depending on the target market for the finished drug product, the API manufacturer may need to undergo specific registration processes or inspections by local regulatory bodies.
• Traceability and Supply Chain Integrity: Robust systems for lot traceability and supply chain security are essential to prevent counterfeiting and ensure that the API originates from an approved and audited source.

Pharmacopoeial Standards:

Chloroprocaine hydrochloride API must meet the specifications outlined in major pharmacopoeias, including:

• United States Pharmacopeia (USP): Specifies tests and acceptance criteria for identity, assay, impurities, and other quality attributes.
• European Pharmacopoeia (EP): Provides similar monograph standards for the quality of the API.
• Japanese Pharmacopoeia (JP): Offers relevant standards for markets in Japan.

Compliance with these pharmacopoeias is a prerequisite for market entry in their respective regions.

What is the Patent Landscape for Chloroprocaine Hydrochloride API Production and Use?

The patent landscape for chloroprocaine hydrochloride itself is largely historical, as the compound has been in use for many decades. However, patents may still be relevant concerning novel synthesis routes, purification methods, polymorphic forms, or specific pharmaceutical compositions and therapeutic uses.

Historical Context:

Chloroprocaine hydrochloride was first developed in the mid-20th century. Patents covering the basic molecule and its initial synthesis have long expired. This means the compound is generally considered off-patent for its basic therapeutic use as a local anesthetic.

Areas of Potential Current Patent Activity:

• Novel Synthesis Processes: While fundamental synthesis routes are known, companies may develop and patent improved, more efficient, cost-effective, or environmentally friendly methods for producing chloroprocaine hydrochloride. This could involve new catalysts, reaction conditions, or purification techniques.
• Polymorphic Forms: The discovery and patenting of specific crystalline forms (polymorphs) of chloroprocaine hydrochloride with enhanced stability, solubility, or bioavailability can be a source of intellectual property.
• Formulations and Drug Delivery Systems: Patents are frequently granted for novel pharmaceutical formulations that incorporate chloroprocaine hydrochloride. This includes:
  • Extended-release formulations: Developing systems that prolong the anesthetic effect.
  • Combination therapies: Formulations combining chloroprocaine hydrochloride with other active ingredients.
  • Injectable solutions with improved stability or reduced side effects: Innovations in excipients or stabilization techniques.
  • Topical formulations: Development of creams, gels, or patches for specific applications.
• Therapeutic Uses: While its primary use is established, patents might exist for new or niche therapeutic applications of chloroprocaine hydrochloride, potentially in combination with other agents or for specific medical conditions.
• Impurity Reduction Technologies: Patents might cover specific methods or technologies developed to reduce or eliminate critical impurities during the manufacturing process.

Implications for Sourcing:

• Freedom to Operate (FTO): When sourcing API for generic drug product manufacturing, companies must conduct thorough FTO analyses to ensure their chosen synthesis route and intended use do not infringe on existing, unexpired patents.
• Innovation in Manufacturing: Companies developing new synthesis patents can create competitive advantages by offering higher purity API or lower production costs.
• Formulation Patent Protection: Pharmaceutical companies developing new drug products utilizing chloroprocaine hydrochloride will seek patent protection for their novel formulations and uses. This does not directly impact API sourcing but influences the market for finished products.

A comprehensive patent search, focusing on recent patent filings related to chemical synthesis, polymorphic forms, and pharmaceutical compositions involving chloroprocaine hydrochloride, is recommended for any company entering or expanding in this market.

Key Takeaways

• China and India are the primary global manufacturing hubs for chloroprocaine hydrochloride API, with Europe and North America also contributing to supply.
• Key suppliers include Xiamen Origin Chemical, Changzhou Finer Chemical, Gennex Laboratories, and Alkem Laboratories, among others.
• API pricing ranges from approximately $40 to $90 USD per kilogram, influenced by raw material costs, manufacturing scale, and regulatory compliance.
• Critical regulatory considerations include GMP compliance, availability of DMFs/CEPs, impurity control, and adherence to pharmacopoeial standards (USP, EP).
• While the basic molecule is off-patent, innovation may persist in novel synthesis routes, polymorphic forms, and specific pharmaceutical formulations or therapeutic uses.

Frequently Asked Questions

1. Are there any known supply chain vulnerabilities specific to chloroprocaine hydrochloride API production? Supply chain vulnerabilities are primarily linked to broader geopolitical events, raw material price volatility, and regulatory changes impacting major production regions like China and India, rather than unique vulnerabilities specific to chloroprocaine hydrochloride itself.

2. What is the typical lead time for ordering bulk chloroprocaine hydrochloride API from major suppliers? Typical lead times can range from 4 to 12 weeks, depending on the supplier's existing stock, production schedules, order volume, and the buyer's location. Expedited orders may incur additional costs.

3. How does the stability of chloroprocaine hydrochloride API vary between different manufacturers? Stability is primarily dictated by the inherent chemical properties of the API and its purity, which is controlled by the manufacturer's synthesis and purification processes, not by the manufacturer per se, assuming adherence to pharmacopoeial standards. Consistent quality control is key.

4. Can chloroprocaine hydrochloride API be sourced with specific particle size distributions? Yes, depending on the supplier's capabilities and the customer's specific requirements, chloroprocaine hydrochloride API can often be manufactured or milled to achieve desired particle size distributions for downstream processing.

5. What are the essential quality control tests that a buyer should require from an API supplier? Essential quality control tests include identity confirmation (e.g., FTIR, HPLC), assay for potency (e.g., titration, HPLC), identification and quantification of impurities (e.g., related substances by HPLC), residual solvents (e.g., GC), heavy metals, and loss on drying.

Citations

[1] United States Pharmacopeia. (n.d.). Chloroprocaine Hydrochloride. Retrieved from USP-NF. [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from EDQM website. [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from FDA website. [4] Market research reports and trade data from pharmaceutical chemical distributors and analytics firms (specific reports not publicly cited due to proprietary nature). [5] Publicly available company websites and product catalogs of listed API manufacturers.